JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Taki, J.
Right arrow Articles by Tonami, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Taki, J.
Right arrow Articles by Tonami, N.
Journal of Nuclear Medicine Vol. 42 No. 10 1457-1463
© 2001 by Society of Nuclear Medicine


Clinical Investigations

99mTc-Sestamibi Retention Characteristics During Pharmacologic Hyperemia in Human Myocardium: Comparison with Coronary Flow Reserve Measured by Doppler Flowire

Junichi Taki, Susumu Fujino, Kenichi Nakajima, Ichiro Matsunari, Hideaki Okazaki, Takashi Saga, Hisashi Bunko and Norihisa Tonami

Department of Nuclear Medicine, Kanazawa University School of Medicine, Kanazawa; and Department of Cardiology, Fukui Prefectural Hospital, Fukui, Japan

The aim of the study was to investigate the increase in myocardial 99mTc-methoxyisobutylisonitrile (sestamibi) retention in humans during pharmacologic vasodilation. Methods: For calculation of the increase in 99mTc-sestamibi retention during hyperemia, baseline and adenosine triphosphate (ATP)–induced hyperemic stress sestamibi studies were performed using a same-day rest–stress protocol. On the injection of sestamibi, left ventricular dynamic data were obtained for 90 s. The increase in sestamibi retention from baseline to hyperemia was calculated by the formula

where Cmh(t) and Cmb(t) are myocardial counts on the tomographic image, and Cbb({tau}) and Cbh({tau}) are the left ventricular blood-pool counts during the first transit of sestamibi at baseline and during hyperemia, respectively. Coronary flow increase during intravenous ATP stress was measured using intracoronary Doppler flow guide wire and compared with the scintigraphic results of 28 measurements in 22 patients. Results: Sestamibi retention increased as coronary flow velocity increased but plateaued at >2.5–3 times baseline flow velocity. The relationship between the increase in sestamibi retention (Y) and the increase in flow (X) is expressed as follows: Y = 0.44 + 0.60X - 0.068X2 (r = 0.82). Conclusion: In humans, the increase in 99mTc-sestamibi myocardial retention underestimates coronary flow reserve, particularly at high flow rates. Knowledge of these tracer retention characteristics will contribute to a more comprehensive understanding of the manner and interpretation of stress sestamibi imaging.

Key Words: 99mTc-sestamibi • coronary flow reserve • myocardial tracer retention • pharmacologic hyperemia




This article has been cited by other articles:


Home page
JNMHome page
T. Pellegrino, G. Storto, P. P. Filardi, A. R. Sorrentino, A. Silvestro, M. Petretta, G. Brevetti, M. Chiariello, M. Salvatore, and A. Cuocolo
Relationship Between Brachial Artery Flow-Mediated Dilation and Coronary Flow Reserve in Patients with Peripheral Artery Disease
J. Nucl. Med., December 1, 2005; 46(12): 1997 - 2002.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
M. L. E. Vicario, L. Cirillo, G. Storto, T. Pellegrino, N. Ragone, L. Fontanella, M. Petretta, D. Bonaduce, and A. Cuocolo
Influence of Risk Factors on Coronary Flow Reserve in Patients with 1-Vessel Coronary Artery Disease
J. Nucl. Med., September 1, 2005; 46(9): 1438 - 1443.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2001 by the Society of Nuclear Medicine.